Matinas BioPharma Inc. (MTNB)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.56 |
Market Cap | 2.92M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -4.74 |
PE Ratio (ttm) | -0.12 |
Forward PE | n/a |
Analyst | Hold |
Ask | 0.58 |
Volume | 28,311 |
Avg. Volume (20D) | 496,036 |
Open | 0.59 |
Previous Close | 0.58 |
Day's Range | 0.56 - 0.59 |
52-Week Range | 0.48 - 21.50 |
Beta | undefined |
About MTNB
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a presc...
Analyst Forecast
According to 1 analyst ratings, the average rating for MTNB stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Why Price Moved
News

5 months ago · seekingalpha.com
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call TranscriptMatinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Jody Cain – LHA Investor Relations Jerry Jabbour – Chief Executive Office...

9 months ago · seekingalpha.com
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call TranscriptMatinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer T...

2 years ago · seekingalpha.com
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2022 Earnings Call TranscriptMatinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2022 Results Conference Call November 2, 2022 4:30 PM ET Company Participants Ankit Bhargava - Investor Relations Jerry Jabbour - Chief Executive Offic...